There are 304 resources available
120MO - Adjuvant Pembrolizumab versus Placebo for Early-Stage NSCLC After Resection and Optional Chemotherapy: Updated Results From PEARLS/KEYNOTE-091
Presenter: Benjamin Besse
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant 67MO, LBA4 and 120MO
Presenter: Stephane Champiat
Session: Mini Oral session
Resources:
Slides
Webcast
Introduction and first vote
Presenter: E.G. Elisabeth de Vries
Session: Cell therapy vs bispecific antibodies
Resources:
Slides
Webcast
Bispecific antibodies
Presenter: Martin Hutchings
Session: Cell therapy vs bispecific antibodies
Resources:
Slides
Webcast
Immunotherapy combinations in early stage NSCLC
Presenter: Tina Cascone
Session: The future of immunotherapy in thoracic oncology
Resources:
Slides
Webcast
Mechanisms employed by the tumour microbiome to mediate responses to immunotherapy
Presenter: Florencia McAllister
Session: Anti-cancer pathogen-derived therapies
Resources:
Slides
Webcast
Dressing up viruses to fool cancer: Personalised oncolytic vaccine for solid tumours
Presenter: Vincenzo Cerullo
Session: Anti-cancer pathogen-derived therapies
Resources:
Slides
Webcast
Immunotherapy plus targeted therapy combinations: Promises and pitfalls
Presenter: Jarushka Naidoo
Session: The future of immunotherapy in thoracic oncology
Resources:
Slides
Webcast
Second vote and conclusions
Presenter: E.G. Elisabeth de Vries
Session: Cell therapy vs bispecific antibodies
Resources:
Slides
Webcast
Next-generation biomarkers of immunotherapy in NSCLC
Presenter: Alessandra Curioni-Fontecedro
Session: The future of immunotherapy in thoracic oncology
Resources:
Slides
Webcast